FDA Strategizes to Step Up Introduction of Lower-Cost Drugs and NGS
The market for biosimilar introduction is “extremely unstable,” but the FDA is working to ease the launch of more affordable cancer medicines with a strategy that includes an attempt to reduce anticompetitive behavior.
Source: OncLive
* Five Most Promising Investment Trends to Capitalize On in 2021
* Improving Your Security Online: 4 Simple Steps




